Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Jupiter Neurosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Jupiter Neurosciences, Inc.’s stock price such as:

• Jupiter Neurosciences, Inc.’s current stock price and volume
• Why Jupiter Neurosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for JUNS from analysts
• JUNS’s stock price momentum as measured by its relative strength

About Jupiter Neurosciences, Inc. (JUNS)

Before we jump into Jupiter Neurosciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson’s disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Want to learn more about Jupiter Neurosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Jupiter Neurosciences, Inc..

Jupiter Neurosciences, Inc.’s Stock Price as of Market Close

As of March 31, 2026, 12:38 PM, CST, Jupiter Neurosciences, Inc.’s stock price was $0.340.

Jupiter Neurosciences, Inc. is up 4.62% from its previous closing price of $0.325.

During the last market session, Jupiter Neurosciences, Inc.’s stock traded between $0.318 and $0.340. Currently, there are approximately 34.04 million shares outstanding for Jupiter Neurosciences, Inc..

Jupiter Neurosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Jupiter Neurosciences, Inc. Stock Price History

Jupiter Neurosciences, Inc.’s (JUNS) price is currently down 35.89% so far this month.

During the month of March, Jupiter Neurosciences, Inc.’s stock price has reached a high of $0.530 and a low of $0.306.

Over the last year, Jupiter Neurosciences, Inc. has hit prices as high as $3.330 and as low as $0.306. Year to date, Jupiter Neurosciences, Inc.’s stock is down 66.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Jupiter Neurosciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 30, 2026, there were analysts who downgraded Jupiter Neurosciences, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Jupiter Neurosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Jupiter Neurosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Jupiter Neurosciences, Inc. (JUNS) by visiting AAII Stock Evaluator.

Relative Price Strength of Jupiter Neurosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 30, 2026, Jupiter Neurosciences, Inc. has a weighted four-quarter relative price strength of -16.50%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Jupiter Neurosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Jupiter Neurosciences, Inc. Stock Price: Bottom Line

As of March 31, 2026, Jupiter Neurosciences, Inc.’s stock price is $0.340, which is up 4.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Jupiter Neurosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.